Alnylam Pharmaceuticals, Inc.
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
Last updated:
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
Status:
Grant
Type:
Utility
Filling date:
19 Dec 2017
Issue date:
12 Nov 2019